HBV DNA appears earlier than HBsAg during the early stages of HBV infection and serves as an important marker for assessing viral replication and disease progression. Quantification of HBV DNA also plays a critical role in monitoring antiviral treatment response and supporting the evaluation of long-term treatment outcomes, including strategies aimed at clinical cure and hepatocellular carcinoma prevention. The HBV DNA Quantitative Testing Service provided by IMPMM is powered by SUPBIO Microscale-Precision Technologies, delivering high sensitivity and reliable performance for evaluating HBV replication levels and supporting clinical decision-making and long-term patient management.
IMPMM
Institute for Macroscale and Precision Medical Measurement
Institute for Macroscale and Precision Medical Measurement
An independent clinical laboratory established through collaboration between Jinan University and Supbio
